Hepa Thera

PharmaceuticalsSeries BShanghai, Chinahepathera.com

Latest round

Series B

Last raised

May 2026

Total raised

$98M

Investors

8

About Hepa Thera

, Ltd. provides therapeutic treatments for the biopharmaceutical sector. The CEO of the company, Yanqin Ma, was the vice president of Jiangsu Enhua Pharmaceutical Research Institute, and the CMO, Shanzhong Zhang, worked at Shanghai First People's Hospital. The company works with research institutions and medical networks to provide liver disease treatments through a combination of proprietary research and licensed assets. Its core pipeline includes the HT-101 small interfering RNA injection and the HT-102 neutralizing antibody, which are utilized as a combination therapy to treat chronic hepatitis B. The company generates revenue from business-to-business contracts through the licensing, collaborative development, and commercialization of its therapeutic drug pipelines and pipeline assets.

Who invested in Hepa Thera

8 investors across 2 rounds

See all investors in Hepa Thera

Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.

Funding rounds

  1. Series B

    May 29, 2026

    Amount

    $93M

    Investors

    Locked

  2. Seed

    Jul 28, 2021

    Amount

    $4.6M

    Investors

    Locked

Questions about Hepa Thera

Who invested in Hepa Thera?

Hepa Thera has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.

How much funding has Hepa Thera raised?

Hepa Thera has raised 2 venture rounds. Sign up free to see how much each round raised and the total.

When did Hepa Thera last raise money?

Hepa Thera's most recent round on record is a Series B, in May 2026.

What does Hepa Thera do?

Hepa Thera is a pharmaceuticals company.

Where is Hepa Thera headquartered?

Hepa Thera is headquartered in Shanghai, China.

Which VCs invest in companies like Hepa Thera?

Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at Hepa Thera's stage. Their profiles are linked below.

Raising like Hepa Thera? Find the right VCs.

Capital Atlas matches your startup to active investors by stage, sector and region.

Free to start. Upgrade when you're ready to reach out.